# These are extra modification we can do to make our project/paper more significant#

Suggested by Claude.

The modifications that make it publishable
These are the specific angles that differentiate your work from existing papers:

Breast cancer cell-line conditioning — don't just predict population-level SL pairs. Condition your model on CCLE expression profiles from breast cancer lines (MCF7, MDA-MB-231, HCC1143 for TNBC). Existing GNN methods designed for population-based SL prediction have limitations when adapted for cell-specific SL prediction, and none have integrated multiple biological graph features simultaneously for this task. That's your gap. Frontiers



--- 

TNBC focus — Triple-negative breast cancer has no targeted therapies and the poorest prognosis. Framing your model around TNBC SL prediction has immediate clinical narrative and reviewer appeal.

---

Negative sampling rigor — improving data quality by excluding computationally derived SL pairs from training and sampling negatives based on gene expression gives the biggest performance gains across all methods. Make this a core methodological contribution, not an afterthought. PubMed Central

---
Subgraph explainability — tie every novel SL prediction back to a biological pathway. This is the bridge between ML and biology that most papers skip and reviewers demand.

---
Drug repurposing endpoint — connect top predictions to approved drugs. The SynLethDB 2.0 framework demonstrates this workflow: BRCA1's SL partner PARP2 leads directly to FDA-approved drugs rucaparib, talazoparib, niraparib, and olaparib — showing how the SL-to-drug pipeline works in practice. Replicate this end-to-end for your novel predictions. Oxford Academic


